|108.41||+0.6700||+0.62%||Vol 4.63M||1Y Perf 26.62%|
|Mar 1st, 2021 16:03 DELAYED|
|- -||-0.21 -0.19%|
|Target Price||116.73||Analyst Rating||Moderate Buy 1.64|
|Potential %||7.67||Finscreener Ranking||★+ 44.45|
|Insiders Trans % 3/6/12 mo.||-100/-100/-52||Value Ranking||★+ 45.06|
|Insiders Value % 3/6/12 mo.||-100/-100/-98||Growth Ranking||★★ 45.24|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-97||Income Ranking||★★★ 45.40|
|Market Cap||191.44B||Earnings Rating||Sell|
|Price Range Ratio 52W %||90.17||Earnings Date||3rd Feb 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||2.85|
|EPS Growth Next 5 Years %||4.80|
|Avg. Weekly Volume||6.67M|
|Avg. Monthly Volume||7.28M|
|Avg. Quarterly Volume||7.15M|
AbbVie Inc. (NYSE: ABBV) stock closed at 108.41 per share at the end of the most recent trading day (a 0.62% change compared to the prior day closing price) with a volume of 4.71M shares and market capitalization of 191.44B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30000 people. AbbVie Inc. CEO is Richard A. Gonzalez.
The one-year performance of AbbVie Inc. stock is 26.62%, while year-to-date (YTD) performance is 1.18%. ABBV stock has a five-year performance of 94.63%. Its 52-week range is between 62.55 and 113.41, which gives ABBV stock a 52-week price range ratio of 90.17%
AbbVie Inc. currently has a PE ratio of 38.50, a price-to-book (PB) ratio of 14.55, a price-to-sale (PS) ratio of 4.18, a price to cashflow ratio of 10.20, a PEG ratio of 2.32, a ROA of 3.68%, a ROC of 14.01% and a ROE of 218.05%. The company’s profit margin is 10.22%, its EBITDA margin is 26.90%, and its revenue ttm is $45.80 Billion , which makes it $25.94 revenue per share.
Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.85 for the next earnings report. AbbVie Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.64), with a target price of $116.73, which is +7.67% compared to the current price. The earnings rating for AbbVie Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AbbVie Inc. has a dividend yield of 4.80% with a dividend per share of $5.20 and a payout ratio of 98.00%.
AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.84, ATR14 : 3.28, CCI20 : 67.86, Chaikin Money Flow : -0.05, MACD : 0.19, Money Flow Index : 53.74, ROC : 3.55, RSI : 54.49, STOCH (14,3) : 72.97, STOCH RSI : 0.68, UO : 52.36, Williams %R : -27.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Azita Saleki-Gerhardt (Option Excercise at a value of $116 199), Azita Saleki-Gerhardt (Sold 22 226 shares of value $2 157 076 ), Brian L. Durkin (Buy at a value of $362 705), Carlos Alban (Option Excercise at a value of $4 155 980), Carlos Alban (Sold 169 155 shares of value $16 915 554 ), Edward J. Rapp (Buy at a value of $505 234), Elaine K. Sorg (Option Excercise at a value of $1 813 052), Elaine K. Sorg (Sold 20 195 shares of value $2 114 732 ), Henry O. Gosebruch (Sold 40 000 shares of value $3 975 046 ), Jeffrey Ryan Stewart (Option Excercise at a value of $2 600 822), Jeffrey Ryan Stewart (Sold 96 628 shares of value $9 455 320 ), Michael Severino (Sold 90 679 shares of value $8 488 461 ), Richard A. Gonzalez (Option Excercise at a value of $11 089 858), Richard A. Gonzalez (Sold 231 604 shares of value $22 437 252 ), Timothy J. Richmond (Option Excercise at a value of $2 673 325), Timothy J. Richmond (Sold 71 435 shares of value $7 111 775 )
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.